All data are based on the daily closing price as of June 6, 2025
c
CHO Pharma
6586.TWO
1.34 USD
0.00
0.00%
Overview
Last close
1.34 usd
Market cap
287.42M usd
52 week high
2.25 usd
52 week low
1.18 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
2403.1292
Price/Book Value
3.1299
Enterprise Value
209.43M usd
EV/Revenue
1750.3375
EV/EBITDA
-34.5511
Key financials
Revenue TTM
119652.41 usd
Gross Profit TTM
57152.41 usd
EBITDA TTM
-7.94M usd
Earnings per Share
-0.03 usd
Dividend
N/A usd
Total assets
92.60M usd
Net debt
-2.95M usd
About
CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which is in Phase I/IIa clinical trials for the treatment of refractory non-Hodgkin lymphoma; CHO-A04, a humanized monoclonal antibody, which is in phase I clinical trials to treat various tumor and cancer stem cells; and CHO-V08 vaccines for the treatment of klebsiella pneumonia. Further, it develops CHO-H02 that is in preclinical stage to target solid tumors, including breast, bladder, pancreatic, ovarian, and gastric cancers; and CHO-H03, an antibody drug that is in pre-clinical development stage indicated for inflammatory conditions in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in Taipei City, Taiwan.